Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, Stephan J, Mangana J, Kunstfeld R, Pehamberger H, Aebersold R, Dummer R, Levesque MP.

EMBO J. 2019 Jun 26:e95874. doi: 10.15252/embj.201695874. [Epub ahead of print]

PMID:
31267558
2.

SMAD signaling promotes melanoma metastasis independently of phenotype switching.

Tuncer E, Calçada RR, Zingg D, Varum S, Cheng P, Freiberger SN, Deng CX, Kleiter I, Levesque MP, Dummer R, Sommer L.

J Clin Invest. 2019 Apr 30;130:2702-2716. doi: 10.1172/JCI94295.

3.

Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation.

Varum S, Baggiolini A, Zurkirchen L, Atak ZK, Cantù C, Marzorati E, Bossart R, Wouters J, Häusel J, Tuncer E, Zingg D, Veen D, John N, Balz M, Levesque MP, Basler K, Aerts S, Zamboni N, Dummer R, Sommer L.

Cell Stem Cell. 2019 Apr 4;24(4):637-653.e9. doi: 10.1016/j.stem.2019.03.011.

PMID:
30951662
4.

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.

Li Y, Tinoco R, Elmén L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y, Khateb A, Frederick DT, Ashkenazi SK, Kim H, Perez EG, Day CP, Segura Muñoz RS, Schmaltz R, Yooseph S, Tam MA, Zhang T, Avitan-Hersh E, Tzur L, Roizman S, Boyango I, Bar-Sela G, Orian A, Kaufman RJ, Bosenberg M, Goding CR, Baaten B, Levesque MP, Dummer R, Brown K, Merlino G, Ruppin E, Flaherty K, Ramer-Tait A, Long T, Peterson SN, Bradley LM, Ronai ZA.

Nat Commun. 2019 Apr 2;10(1):1492. doi: 10.1038/s41467-019-09525-y.

5.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.

Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L.

J Immunother Cancer. 2019 Feb 20;7(1):50. doi: 10.1186/s40425-019-0523-2.

6.

Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.

Poźniak J, Nsengimana J, Laye JP, O'Shea SJ, Diaz JMS, Droop AP, Filia A, Harland M, Davies JR, Mell T, Randerson-Moor JA, Muralidhar S, Hogan SA, Freiberger SN, Levesque MP, Cook GP, Bishop DT, Newton-Bishop J.

Cancer Res. 2019 May 15;79(10):2684-2696. doi: 10.1158/0008-5472.CAN-18-2864. Epub 2019 Feb 17.

PMID:
30773503
7.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.

Diem S, Fässler M, Bomze D, Ali OH, Berner F, Niederer R, Hillmann D, Mangana J, Levesque MP, Dummer R, Risch L, Recher M, Risch M, Flatz L.

J Immunother. 2019 Apr;42(3):89-93. doi: 10.1097/CJI.0000000000000255.

PMID:
30768543
8.

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. No abstract available.

PMID:
30510016
9.

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MIG, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP.

Cancer Immunol Res. 2019 Jan;7(1):77-85. doi: 10.1158/2326-6066.CIR-18-0136. Epub 2018 Nov 13.

PMID:
30425105
10.

SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics.

Singer F, Irmisch A, Toussaint NC, Grob L, Singer J, Thurnherr T, Beerenwinkel N, Levesque MP, Dummer R, Quagliata L, Rothschild SI, Wicki A, Beisel C, Stekhoven DJ.

BMC Med Inform Decis Mak. 2018 Oct 29;18(1):89. doi: 10.1186/s12911-018-0680-0.

11.

Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.

Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW, Dummer R.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):667-675. doi: 10.1111/jdv.15302. Epub 2018 Nov 26.

PMID:
30357969
12.

Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.

Pich C, Meylan P, Mastelic-Gavillet B, Nguyen TN, Loyon R, Trang BK, Moser H, Moret C, Goepfert C, Hafner J, Levesque MP, Romero P, Jandus C, Michalik L.

Cancer Res. 2018 Nov 15;78(22):6447-6461. doi: 10.1158/0008-5472.CAN-18-0912. Epub 2018 Sep 5.

PMID:
30185551
13.

Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread.

Ma Q, Dieterich LC, Ikenberg K, Bachmann SB, Mangana J, Proulx ST, Amann VC, Levesque MP, Dummer R, Baluk P, McDonald DM, Detmar M.

Sci Adv. 2018 Aug 8;4(8):eaat4758. doi: 10.1126/sciadv.aat4758. eCollection 2018 Aug.

14.

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.

Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L.

Cancer Cell. 2018 Jul 9;34(1):69-84.e14. doi: 10.1016/j.ccell.2018.06.001. Epub 2018 Jun 28.

15.

Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B.

Nat Med. 2018 Nov;24(11):1773-1775. doi: 10.1038/s41591-018-0094-7.

PMID:
29967347
16.

Melanoma Immunotherapy: Next-Generation Biomarkers.

Hogan SA, Levesque MP, Cheng PF.

Front Oncol. 2018 May 29;8:178. doi: 10.3389/fonc.2018.00178. eCollection 2018. Review.

17.

VLA-4 mediated adhesion of melanoma cells on the blood-brain barrier is the critical cue for melanoma cell intercalation and barrier disruption.

García-Martín AB, Zwicky P, Gruber T, Matti C, Moalli F, Stein JV, Francisco D, Enzmann G, Levesque MP, Hewer E, Lyck R.

J Cereb Blood Flow Metab. 2018 May 15:271678X18775887. doi: 10.1177/0271678X18775887. [Epub ahead of print]

PMID:
29762071
18.

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.

Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C.

Biol Open. 2018 Jun 7;7(6). pii: bio032656. doi: 10.1242/bio.032656.

19.

Methadone-Not a magic bullet in melanoma therapy.

Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R.

Exp Dermatol. 2018 Jun;27(6):694-696. doi: 10.1111/exd.13543.

PMID:
29577418
20.

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V.

Clin Proteomics. 2018 Mar 9;15:13. doi: 10.1186/s12014-018-9189-x. eCollection 2018.

21.

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Erratum in: Cancer Discov. 2018 Dec;8(12):1654.

22.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

23.

Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L.

Nat Commun. 2018 Jan 22;9(1):314. doi: 10.1038/s41467-018-02850-8.

24.

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B.

Nat Med. 2018 Feb;24(2):144-153. doi: 10.1038/nm.4466. Epub 2018 Jan 8. Erratum in: Nat Med. 2018 Nov;24(11):1773-1775.

PMID:
29309059
25.

Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.

Siliņa K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, Foukas P, Levesque MP, Moch H, Linē A, van den Broek M.

Cancer Res. 2018 Mar 1;78(5):1308-1320. doi: 10.1158/0008-5472.CAN-17-1987. Epub 2017 Dec 26.

26.

Bioinformatics for precision oncology.

Singer J, Irmisch A, Ruscheweyh HJ, Singer F, Toussaint NC, Levesque MP, Stekhoven DJ, Beerenwinkel N.

Brief Bioinform. 2019 May 21;20(3):778-788. doi: 10.1093/bib/bbx143.

27.

low neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L.

Nat Commun. 2017 Dec 7;8(1):1988. doi: 10.1038/s41467-017-01573-6. Erratum in: Nat Commun. 2018 Jan 22;9(1):314.

28.

Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.

Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, Hoffman PS, Oyan AM, Zhang W, Kalland KH, Ke X.

Nat Chem Biol. 2018 Jan;14(1):94-101. doi: 10.1038/nchembio.2510. Epub 2017 Oct 30.

PMID:
29083417
29.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A.

Oncotarget. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213. eCollection 2017 Sep 19.

30.

NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis.

Singer J, Ruscheweyh HJ, Hofmann AL, Thurnherr T, Singer F, Toussaint NC, Ng CKY, Piscuoglio S, Beisel C, Christofori G, Dummer R, Hall MN, Krek W, Levesque MP, Manz MG, Moch H, Papassotiropoulos A, Stekhoven DJ, Wild P, Wüst T, Rinn B, Beerenwinkel N.

Bioinformatics. 2018 Jan 1;34(1):107-108. doi: 10.1093/bioinformatics/btx540.

31.

miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.

Neu J, Dziunycz PJ, Dzung A, Lefort K, Falke M, Denzler R, Freiberger SN, Iotzova-Weiss G, Kuzmanov A, Levesque MP, Dotto GP, Hofbauer GFL.

PLoS One. 2017 Sep 20;12(9):e0185028. doi: 10.1371/journal.pone.0185028. eCollection 2017.

32.

MEK inhibition and immune responses in advanced melanoma.

Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque MP, Koelblinger P.

Oncoimmunology. 2017 Aug 10;6(8):e1335843. doi: 10.1080/2162402X.2017.1335843. eCollection 2017. Review.

33.

HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.

Ishida Y, Otsuka A, Tanaka H, Levesque MP, Dummer R, Kabashima K.

J Invest Dermatol. 2017 Nov;137(11):2443-2444. doi: 10.1016/j.jid.2017.06.023. Epub 2017 Jul 21. No abstract available.

34.

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.

Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL.

Nature. 2017 Jul 27;547(7664):453-457. doi: 10.1038/nature23007. Epub 2017 Jul 5.

35.

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.

Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C.

EMBO Mol Med. 2017 Aug;9(8):1011-1029. doi: 10.15252/emmm.201607156.

36.

CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets.

Nowicka M, Krieg C, Crowell HL, Weber LM, Hartmann FJ, Guglietta S, Becher B, Levesque MP, Robinson MD.

Version 3. F1000Res. 2017 May 26 [revised 2019 Jan 1];6:748. doi: 10.12688/f1000research.11622.3. eCollection 2017.

37.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.

Melanoma Res. 2017 Aug;27(4):358-368. doi: 10.1097/CMR.0000000000000359.

38.

Sox2 is dispensable for primary melanoma and metastasis formation.

Schaefer SM, Segalada C, Cheng PF, Bonalli M, Parfejevs V, Levesque MP, Dummer R, Nicolis SK, Sommer L.

Oncogene. 2017 Aug;36(31):4516-4524. doi: 10.1038/onc.2017.55. Epub 2017 Apr 3.

39.

Metastatic melanoma moves on: translational science in the era of personalized medicine.

Levesque MP, Cheng PF, Raaijmakers MI, Saltari A, Dummer R.

Cancer Metastasis Rev. 2017 Mar;36(1):7-21. doi: 10.1007/s10555-017-9658-0. Review.

PMID:
28321632
40.

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?

Haueis SA, Kränzlin P, Mangana J, Cheng PF, Urosevic-Maiwald M, Braun RP, Levesque MP, Dummer R, Goldinger SM.

Melanoma Res. 2017 Jun;27(3):231-237. doi: 10.1097/CMR.0000000000000338.

41.

Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration.

Farsam V, Basu A, Gatzka M, Treiber N, Schneider LA, Mulaw MA, Lucas T, Kochanek S, Dummer R, Levesque MP, Wlaschek M, Scharffetter-Kochanek K.

Oncotarget. 2016 Dec 13;7(50):83554-83569. doi: 10.18632/oncotarget.13446.

42.

Field spectrometer measurement errors in presence of partially polarized light; evaluation of ground truth measurement accuracy.

Lévesque MP, Dissanska M.

Opt Express. 2016 Nov 28;24(24):27199-27211. doi: 10.1364/OE.24.027199.

PMID:
27906294
43.

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP.

Oncotarget. 2016 Nov 22;7(47):77163-77174. doi: 10.18632/oncotarget.12848.

44.

An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.

Thurneysen S, Cheng PF, Nagel HW, Kunz M, Jaberg-Bentele N, Nägeli M, Ziegler M, Guenova E, Goldinger SM, Mangana J, Levesque MP, Dummer R.

Br J Dermatol. 2016 Nov;175(5):966-978. doi: 10.1111/bjd.14727. Epub 2016 Sep 19.

45.

Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages.

Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque MP, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C, Nonomura Y, Kabashima K, Dummer R, Contassot E, French LE.

Sci Rep. 2016 Jul 18;6:29914. doi: 10.1038/srep29914.

46.

A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis.

Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, Ronai ZA.

Cell Rep. 2016 May 31;15(9):1884-92. doi: 10.1016/j.celrep.2016.04.072. Epub 2016 May 19.

47.

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C.

Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003.

48.

Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.

Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C.

Curr Opin Oncol. 2016 Mar;28(2):172-9. doi: 10.1097/CCO.0000000000000261. Review.

PMID:
26742019
49.

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.

Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R.

Clin Cancer Res. 2016 Apr 15;22(8):2020-31. doi: 10.1158/1078-0432.CCR-15-1435. Epub 2015 Dec 9.

50.

Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations.

Rolfs F, Huber M, Kuehne A, Kramer S, Haertel E, Muzumdar S, Wagner J, Tanner Y, Böhm F, Smola S, Zamboni N, Levesque MP, Dummer R, Beer HD, Hohl D, Werner S, Schäfer M.

Cancer Res. 2015 Nov 15;75(22):4817-29. doi: 10.1158/0008-5472.CAN-15-0614. Epub 2015 Nov 3.

Supplemental Content

Loading ...
Support Center